CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 76 enrolled
Drug / intervention
Vilazodone +1 moredrug
Likely dose
Vilazodone 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01574183
NCT01574183Phase 2Completed

Vilazodone Treatment for Marijuana Dependence

Medical University of South Carolina·interventional·Posted Apr 10, 2012·Updated Aug 10, 2016

In Brief

A Phase 2 clinical trial evaluating Vilazodone and Placebo for Marijuana Dependence. Completed, enrolled 76 participants across 1 site.

Detailed Summary

Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of vilazodone for reducing marijuana use in marijuana-dependent adults. A contingency management intervention (CM)and motivational enhancement therapy (MET)will be incorporated to encourage study engagement and retention, and genomic DNA will be extracted to characterize subjects according to polymorphisms of genes potentially relevant to the activity of vilazodone. It is hypothesized that vilazodone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 10, 2012
Enrollment StartAug 1, 2012
Primary CompletionAug 1, 2015
Study CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 14.2 years ago

Interventions

Vilazodonedrug

up to 40 mg capsule daily

Placebodrug

up to 40 mg capsule daily